TrialClinical cancer research : an official journal of the American Association for Cancer Research2025

Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial.

Holger N Lode et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.